{"pmid":32233755,"title":"Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.","text":["Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.","J Am Heart Assoc","Guo, Junyi","Huang, Zheng","Lin, Li","Lv, Jiagao","32233755"],"journal":"J Am Heart Assoc","authors":["Guo, Junyi","Huang, Zheng","Lin, Li","Lv, Jiagao"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233755","week":"202014|Mar 30 - Apr 05","doi":"10.1161/JAHA.120.016219","keywords":["ACEI/ARB","COVID-19","SARS-CoV-2","angiotensin-converting enzyme 2","cardiovascular disease"],"source":"PubMed","locations":["Onset"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1662996001668988929,"score":7.6048946,"similar":[{"pmid":32208485,"title":"COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","text":["COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","JAMA","Patel, Ankit B","Verma, Ashish","32208485"],"journal":"JAMA","authors":["Patel, Ankit B","Verma, Ashish"],"date":"2020-03-26T11:00:00Z","year":2020,"_id":"32208485","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4812","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663095625845047296,"score":183.13765},{"pmid":32186711,"title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","text":["Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.","J Travel Med","Diaz, James H","32186711"],"abstract":["Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections."],"journal":"J Travel Med","authors":["Diaz, James H"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186711","week":"202012|Mar 16 - Mar 22","doi":"10.1093/jtm/taaa041","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663095625923690496,"score":182.97002},{"pmid":32233753,"title":"Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?","text":["Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?","J Am Heart Assoc","Sommerstein, Rami","Kochen, Michael M","Messerli, Franz H","Grani, Christoph","32233753"],"journal":"J Am Heart Assoc","authors":["Sommerstein, Rami","Kochen, Michael M","Messerli, Franz H","Grani, Christoph"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233753","week":"202014|Mar 30 - Apr 05","doi":"10.1161/JAHA.120.016509","keywords":["ACE2","angiotensin II receptor blocker","angiotensin-converting enzyme inhibitor","coronavirus disease 2019","epidemiology","infectious diseases"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662996001666891776,"score":172.39613},{"pmid":32242182,"title":"A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).","text":["A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).","There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.","N Z Med J","Talreja, Hari","Tan, Jasmine","Dawes, Matt","Supershad, Sharen","Rabindranath, Kannaiyan","Fisher, James","Valappil, Sajed","van der Merwe, Veronica","Wong, Lisa","van der Merwe, Walter","Paton, Julian","32242182"],"abstract":["There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use."],"journal":"N Z Med J","authors":["Talreja, Hari","Tan, Jasmine","Dawes, Matt","Supershad, Sharen","Rabindranath, Kannaiyan","Fisher, James","Valappil, Sajed","van der Merwe, Veronica","Wong, Lisa","van der Merwe, Walter","Paton, Julian"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242182","week":"202014|Mar 30 - Apr 05","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663079112885927936,"score":156.50308},{"pmid":32129518,"title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","text":["Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.","Drug Dev Res","Gurwitz, David","32129518"],"abstract":["At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility."],"journal":"Drug Dev Res","authors":["Gurwitz, David"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129518","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ddr.21656","keywords":["AT1R blockers","COVID-19 epidemic","SARS-CoV-2","angiotensin-converting enzyme 2 (ACE2)","losartan"],"source":"PubMed","locations":["losartan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663095626077831168,"score":122.39968}]}